Hydroxyurea or hydroxycarbamide

An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.

Hydroxyurea or hydroxycarbamide

Hydroxyurea; Hydroxycarbamide; 127-07-1; N-Hydroxyurea; Hydrea

Cytodrox, Durea, Hondrea, Hydab, Hydran, Hydrea, Leukocel, Myelostat, Neodrea, Oxyrea, Riborea, Unidrea, Urdox

hydroxyurea

Well absorbed from the gastrointestinal tract. Hepatic metabolism.

Hydroxyurea has dose-dependent synergistic activity with cisplatin in vitro.  Hydroxyurea showed activity in combination with cisplatin against the CALU-6 and LX-1 human lung xenografts In vivo, but minimal activity was seen with the NCI-H520 or NCI-H460 xenografts. Hydroxyurea was synergistic with cisplatin in the Lewis lung murine xenograft. Sequential exposure to Hydroxyurea 4 hours before cisplatin produced the greatest interaction.

NA

Metastatic, or inoperable carcinoma of the ovary, resistant chronic myelocytic leukemia, melanoma and Sickle-cell anemia.

GI disturbances, renal impairment, pulmonary oedema, dermatological reactions, headache, and dizziness. Disorientation, drowsiness, hallucinations, convulsions, alopecia, bone marrow suppression.

• Impairs immune response to vaccines; possible infection with live vaccines, zidovudine, zalcitabine.
• May precipitate didanosine- or stavudine-induced pancreatitis, hepatotoxicity or neuropathy.
• Fluorouracil may increase potential for neurotoxicity.
• May alter action of phenytoin and oral anticoagulants.
• Modulates cytotoxicity and metabolism of cytarabine. 

Severe bone-marrow suppression, severe anaemia, WBC <3000/mm3 or platelet count <100,000/mm3. Pregnancy and lactation. Hypersensitivity.

Store at 25°C

Molecular weight

76.0547

Molecular formula

CH4N2O2

CAS number

127-07-1

Precautions

Regular monitoring of uric acid concentrations, blood counts, renal and hepatic function is recommended. Prior irradiation therapy. Elderly. Avoid use of live vaccines.